Zimmer Biomet Holdings 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Zimmer Biomet reported 3rd quarter 2026 net sales of $2.063 billion, up 3.1% reported and 3.7% on a constant currency basis versus the 3rd quarter of 2025; excluding the one-time China distributor network consolidation headwind, constant currency growth would have been 4.7%.
- Two-thirds of the business grew at upper single-digit or double-digit rates; hips grew 7% on a constant currency basis, ACT grew 7.1%, and Technology, Data, Bone Cement, and Surgical grew 13%.
- Global knees declined 2.6% on a constant currency basis, including decreases of 2% in the U.S. and 3.4% internationally; without China headwinds, global knees would have been flat year over year.
- Paragon 28 sales grew over 18%, approaching 20% growth, while robotics, data, and AI solutions grew 20%.
- GAAP diluted earnings per share was $1, compared with $1.16 in the 3rd quarter of 2025; adjusted earnings per share was $1.90, flat with the prior year quarter.
- Adjusted gross margin was 71.7%, down 90 basis points year over year, and adjusted operating margin was 25.1%, down 140 basis points.
- Operating cash flow was $560 million and free cash flow was $372 million, both up about 34% year over year; the company ended the quarter with approximately $400 million in cash and cash equivalents.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet Third Quarter 2026 Earnings Conference Call. If anyone needs assistance at any time during the conference, please press the star followed by the zero. As a reminder, this conference is being recorded today, November 4, 2026. Following today's presentation, there will be a question-and-answer session. At this time, all participants are in a listen-only mode. If you have a question, please press the star followed by the one on your push-button phone. I would now like to turn the conference over to David DeMartino, Senior Vice President, Investor Relations.
Please go ahead. Thank you, operator, and good morning, everyone.
Welcome to Zimmer Biomet's Third Quarter 2026 Earnings Conference Call. Joining me on today's call are Ivan Tornos, our Chairman, President, and CEO, and Paul Stellato, our Interim CFO and VP Controller and Chief Accounting Officer. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. For a detailed discussion of all these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements, please refer to our SEC filings. Please note, we assume no obligation to update these forward-looking statements, even if actual results or future expectations change materially. Additionally, the discussions on this call will include certain non-GAAP financial measures, some of which are forward-looking non-GAAP financial measures.
Reconciliation on these measures to the most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures is included within our third quarter earnings release, which can be found on our website, zimmerbiomet.com. With that, I'll turn the call over to Ivan.
Ivan? Thank you, David. Good morning, everyone, and thank you for joining today's call.
I would like to start, as I always do, by thanking the more than 17,000 global Zimmer Biomet team members for your commitment, your resilience, and most importantly, your dedication to serving our customers and their patients each and every day. I'm grateful to work alongside you, and I'm proud of the noble work we do to alleviate pain and improve the quality of life for people around the world. Roughly six months from now, we'll be celebrating our 100-year anniversary as a company. As I often tell all of you, we are just getting started. Our boldest chapter remains ahead. During my prepared remarks this morning, I'll cover three things. First, I'll review our third quarter performance. Second, I'll discuss our increased outlook for 2026.
And third, I will provide an update on our three strategic priorities, which remain the same: people and culture, operational excellence, and innovation and diversification. To begin, we delivered total net sales of $2.063 billion, resulting in 3.1% reported growth and 3.7% constant currency growth in the quarter compared to the third quarter of 2025. Excluding the negative impact of our China distributor network consolidation strategy, a one-time headwind in fiscal year 2026, our constant currency growth in the quarter would have been 4.7%. Notably, in the period, two-thirds of our book of business grew at least upper single-digit or double-digit rates, validating the strength of our innovation cycle, the improvement in our commercial execution efforts, and the resilience of our global market environment.
In addition, these results are a testament to our efforts to diversify our portfolio over the last six years as we continue to shift from a primarily joint reconstruction company to a broadly diversified business with leading platforms across S.E.T., technology, and higher growth segments within core orthopedics. We are very proud of these quarter results, as our hips and S.E.T. businesses grew upper single digits, and technology and data, bone cement, and surgical grew in the teens, driven by 20% growth in robotics, data, and AI solutions. Furthermore, we are thrilled with the performance of our Paragon 28 acquisition, which continues to grow at roughly three times the foot and ankle market, approaching 20% growth, which we do believe is sustainable. Altogether, this broad-based performance more than offset the expected challenges in our knee business and China.
Turning to our product categories, starting with hips, our global hip business grew 7% on a constant currency basis in the third quarter, with growth of 5.8% in the U.S. and 8.2% internationally. U.S. hip growth continues to be driven by our new product, Cyclar Strength, which includes Z1 or triple taper hip stem, which now represents over 50% of all U.S. hip stems, up from about 40% in the second quarter of this year. HAMMR, or surgical impactor, which is now being used in nearly 30% of all U.S. primary hip cases, is also a major catalyst. Third, OrthoGrid, which delivered its strongest quarter to date, with over two-thirds of sales coming from recurring revenue. OrthoGrid is a clear differentiator for Zimmer Biomet, and we look forward to its global expansion.
Outside the U.S., we continue to build momentum with our iodine-coated hip stem and cup in Japan. This launch has far exceeded our high expectations, and we are rapidly increasing supply to meet the greater-than-expected demand from both existing customers and the new accounts that we are opening. In addition, we are working on launch plans for other geographies outside of Japan. Turning to knees, as anticipated, the knee business continued to face headwinds during the quarter, with sales declining 2.6% on a constant currency basis, including decreases of 2% in the U.S. and 3.4% internationally. The U.S. results reflect the known impact of our sales force transition and a highly competitive knee implant market, while international knees continue to face pressure, most significantly from China headwinds, without which global knees would have been flat year-over-year this last third quarter.
While we continue to expect ongoing pressure in the near term in our knee business, we are confident in our strategy and plan to return to sustainable growth over the long term by, number one, improving commercial execution. It is important to note that the U.S. sales force transition is nearing the halfway mark, and we started to see pockets of meaningful improvement across a variety of U.S. territories. Second, expanding our suite of robotics and enabling technology to meet the diverse needs of a wide array of surgeons around the world. We recently announced a multi-year limited distribution and supply agreement with THINK Surgical to distribute an exclusive version of the only wireless handheld TMINI miniature robotic system compatible with Persona Knee. Most excitingly, we expect to file Monogram's 510(k) application with the FDA very soon, which is significantly ahead of schedule.
We now anticipate that we can launch a surgeon-guided, fully autonomous version of Monogram in the first half of 2027, as opposed to the original expectation of a 2028 launch. We truly believe that this technology will represent a dramatic leap forward for the future of orthopedic care. We will be bringing Monogram to the American Association of Hip and Knee Surgeons annual meeting later this week in Dallas to obtain additional feedback on the system's workflow from surgeons. Our plan to hire at least 225 robotic sales specialists also remains very much on track. Lastly, from a global standpoint, the China-related headwinds will anniversary in January of 2027, giving us visibility into improved global knee performance. SET accelerated to 7.1% growth on a constant currency basis in the quarter, including mid-single-digit growth in the U.S.
We continue to see strength across our key franchises, including foot and ankle, sports medicine, CMFT, cranio-maxillofacial thoracic, and upper extremities, all of which grew between mid-single digits and high teens in the period. Critically, Paragon 28 sales grew over 18%, demonstrating the successful integration of the business and representing a blueprint for future acquisitions. These results were partially offset by continued pressure in trauma and restorative therapies, both of which declined in the quarter as expected. Technology and data, bone cement, and surgical grew 13% on a constant currency basis in the third quarter, once again led by the strong demand for the robotic offerings, including ROSA with OptimiZe and TMINI. Technology and data sales increased over 30% in the U.S., which validates our strategy of offering a comprehensive suite of customer-centric solutions to surgeons. Turning now to our updated outlook for the remainder of 2026.
With three solid quarters behind and an organic constant currency growth rate of 3.5% year to date, we are once again increasing our full-year outlook. We are now raising our organic constant currency sales growth guidance to a range of 3%-3.5% from 2.25%-3.25%, and raising also our adjusted earnings per share guidance to $8.50-$8.60 from the previous guidance of $8.47-$8.59. This increased outlook captures our expectations for consistent global market dynamics, ongoing risk of U.S. sales force disruption, China-related headwinds to the tune of nearly 100 basis points in the fourth quarter, and roughly 50 basis points for the full year 2026, as well as continued pressure in knees. With that, let us turn to our three strategic priorities: people and culture, operational excellence, and innovation and diversification.
First, people and culture. We continue to make steady progress as we transition to a fully dedicated and specialized sales force in the U.S. We started this initiative in earnest earlier this year, and I'm happy to share that three quarters into an eight-quarter journey, we are proceeding ahead of our expectations with over 75% of our U.S. sales force now being fully dedicated. While we are seeing some disruption associated with this transition, particularly in our knee franchise, overall, it has been less disruptive than we initially anticipated. As part of this strategy, we continue to add sales reps across key growth franchises such as upper extremities, sports medicine, CMFT, robotics, and foot and ankle. We're going to continue to invest back into the business to support a smooth transition, and we're going to manage this project with the rigor that it requires.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
